What is the next step in management for a patient with elevated CA‑125, peritoneal nodularity on imaging, and ascites?

Next Step: Obtain Tissue Diagnosis via Surgical Exploration or Image-Guided Biopsy

The immediate next step is to obtain a definitive tissue diagnosis through surgical staging laparotomy/laparoscopy or image-guided core biopsy, preceded by completion of the diagnostic workup with contrast-enhanced CT of the chest/abdomen/pelvis (if not already done), measurement of CEA and CA 19-9, and consideration of gastrointestinal endoscopy to exclude metastatic disease. 1

Critical Diagnostic Workup Before Tissue Sampling

Complete Imaging Evaluation

• Contrast-enhanced CT of the chest, abdomen, and pelvis is mandatory for complete clinical staging, surgical planning, and to identify potential extra-ovarian primary sites (particularly gastrointestinal or pancreatic origins). 1, 2
• If CT has already been performed and shows peritoneal nodularity with ascites, this supports advanced disease but does not establish the primary site or histologic type. 1

Essential Serum Tumor Markers

• Measure CEA and CA 19-9 in addition to CA-125 to help distinguish primary ovarian mucinous carcinoma from gastrointestinal metastases. 1, 2, 3
• Calculate the CA-125/CEA ratio: A ratio >25 strongly favors ovarian primary, whereas a ratio ≤25 mandates gastrointestinal evaluation including colonoscopy and upper endoscopy. 2, 3
• This distinction is critical because ovarian metastases from gastrointestinal primaries are more common than primary mucinous ovarian tumors, and treatment regimens differ markedly. 2

Gastrointestinal Evaluation When Indicated

• If CEA or CA 19-9 is elevated, or if the CA-125/CEA ratio is ≤25, perform colonoscopy and upper endoscopy to exclude occult colorectal or gastric primaries before proceeding to surgery. 2, 3
• This step prevents misattribution of metastatic gastrointestinal cancer as primary ovarian disease. 2

Tissue Diagnosis: The Definitive Next Step

Surgical Approach (Preferred for Resectable Disease)

• Definitive diagnosis requires histopathologic examination of adequate tumor tissue obtained via staging laparotomy or laparoscopy. 1
• Surgical specimens allow comprehensive staging, cytoreduction if ovarian cancer is confirmed, and sufficient tissue for molecular/genetic testing. 1
• Routine appendectomy should be performed if mucinous histology is suspected based on imaging or intraoperative findings. 2

Image-Guided Core Biopsy (For Unresectable or Neoadjuvant Candidates)

• If the patient has bulky unresectable disease or is not an immediate surgical candidate, obtain image-guided or laparoscopic core biopsy to establish diagnosis before initiating systemic therapy. 1, 2
• Avoid fine-needle aspiration in presumed early-stage disease because capsular rupture and peritoneal spillage can upstage the tumor. 1
• Ensure adequate tissue is obtained for immunohistochemistry (IHC) and molecular testing, especially if neoadjuvant chemotherapy is planned. 1

Cytology Alone Is Insufficient

• Do not rely on ascitic fluid cytology alone to make treatment decisions; a core tissue biopsy is required to confirm diagnosis, determine histologic subtype, and enable molecular testing. 2

Immunohistochemical Panel to Determine Primary Site

Once tissue is obtained, the following IHC markers help differentiate ovarian primary from gastrointestinal metastasis:

• CK7⁺/CK20⁻ or focal CK20⁺ with CA-125⁺ and PAX8⁺ strongly supports primary ovarian mucinous carcinoma. 2
• CK20⁺/CK7⁻ with strong CEA⁺ and CA-125⁻ or focal CA-125⁺ suggests metastatic colorectal adenocarcinoma. 2
• Loss of DPC4 (SMAD4) nuclear staining suggests pancreatic primary (~50% of pancreatic adenocarcinomas lose DPC4), whereas primary ovarian mucinous neoplasms retain DPC4. 2
• Use a panel of multiple immunostains rather than relying on a single marker for accurate classification. 2

Important Differential: Peritoneal Tuberculosis

When to Suspect Tuberculosis

• In premenopausal women or immigrants from high-prevalence countries presenting with ascites, peritoneal nodularity, and elevated CA-125, peritoneal tuberculosis must be excluded. 4, 5, 6, 7, 8
• Peritoneal tuberculosis can mimic advanced ovarian cancer with identical clinical, radiologic, and laboratory findings (including CA-125 levels >1000 U/mL). 4, 5, 7, 8

Diagnostic Approach for Tuberculosis

• Laparoscopy with peritoneal biopsy is the preferred method to diagnose peritoneal tuberculosis and avoid unnecessary radical surgery. 5, 7, 8
• Histopathology showing caseating granulomas with epithelioid cells confirms tuberculosis. 6, 7
• Abdominal paracentesis is not useful for ruling out tuberculosis; acid-fast stain and culture are often negative. 8
• CA-125 normalizes within 1–2 months of anti-tuberculous therapy, making it useful for monitoring treatment response. 6, 7, 8

Critical Pitfalls to Avoid

• Do not assume ovarian primary without first excluding gastrointestinal metastasis, as ovarian metastases from GI primaries are more common than primary mucinous ovarian tumors. 2
• Do not start chemotherapy without a definitive tissue diagnosis, because therapeutic regimens differ markedly between ovarian and gastrointestinal origins. 2
• Do not rely on CA-125 alone for diagnosis or staging; its sensitivity is insufficient for early disease (only 50% of stage I ovarian cancers have elevated CA-125) and its specificity is limited by numerous benign conditions (endometriosis, cirrhosis, heart failure, renal failure). 1, 3
• Do not perform fine-needle aspiration on presumed early-stage ovarian masses due to the risk of tumor rupture and peritoneal contamination. 1
• Do not use ultrasound alone for staging; contrast-enhanced CT of the chest, abdomen, and pelvis is mandatory for comprehensive staging. 1
• In premenopausal women, especially immigrants from tuberculosis-endemic regions, consider laparoscopy with frozen section before extensive surgical debulking to avoid unnecessary radical surgery for benign tuberculosis. 4, 5, 8

Additional Considerations

Genetic Testing

• If ovarian cancer is confirmed, offer BRCA1/2 genetic testing to patients with a family history of breast or ovarian cancer. 1
• Consider Lynch syndrome screening if endometrioid or clear-cell histology is identified, as mismatch-repair gene mutations confer a 10–12% lifetime risk of ovarian cancer. 3

Pleural Effusion Management

• If pleural effusion is present and safely accessible, obtain pleural fluid for cytology to assess for thoracic extension. 1